NuGen M.D. Receives Approval for its Netherlands Site to Manufacture Needle-Free Devices Under ISO 13485 QMS Certificate
18 Oct 2022
Vaccine
TORONTO, ON / ACCESSWIRE / October 18, 2022 / NuGen Medical Devices Inc. (TSXV:NGMD)(OTCQB:NGMDF) ("NuGen'' or the "Company"), a leader in needle-free drug delivery, is pleased to announce that it has received confirmation of its official certification for its wholly owned subsidiary European Pharma Group B.V. has received approval for the manufacturing of needle-free devices at its' site in the Netherlands.
The additional manufacturing site allows NuGen to better serve markets in Europe, the Middle East and the Americas with lower logistical costs as well as reduced trade barriers and supply chain uncertainty It also positions the company to utilize a well-established European supply chain for many of its critical components.
"The manufacturing redundancy was always part of the plan and this is an important step to minimize any potential ruptures in the supply chain while simultaneously breaking down trade barriers." said NuGen CEO Michael Wright. "Receiving this certification for our manufacturing facility in Europe represents the next logical step in our strategic plan in order to better serve our international market,"
About NuGen Medical Devices
NuGen is an emerging specialty medical device company developing the next generation of needle-free technologies and other innovative medical delivery products. The company's products, which include the InsuJet™ and PetJet™ needle-free injection systems, are designed to improve the lives of millions of people and animals. NuGen continues to receive approval in numerous countries, including Canada. NuGen's products are designed for use in several important fields including, but not limited to, diabetes, veterinary medicine, and vaccines.
For More Information visit:
Twitter: @NuGenMD
LinkedIn:
Michael Wright
President and CEO
NuGen Medical Devices Inc.
mw@nugenmd.com
Investor Relations Contact:
Kin Communications Inc.
NGMD@kincommunications.com
(604) 684-6730
Twitter: @KinComm
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this press release include the Company's 2022 objectives of securing additional distribution and sales agreements, making submissions for regulatory approvals and capitalizing on additional market opportunities. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
SOURCE: NuGen Medical Devices Inc.
View source version on accesswire.com:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.